These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 29479934)
1. Is the management of Rh-Rh incompatibility with noninvasive fetal Rh genotyping for targeted prophylaxis cost-effective in the Turkish population? Demirel E; Kelekçi S; Ekmekci E; Şengül M; İri R; Atasever M Turk J Med Sci; 2018 Feb; 48(1):1-4. PubMed ID: 29479934 [TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of the management of rh-negative pregnant women. Duplantie J; Gonzales OM; Bois A; Nshimyumukiza L; Gekas J; Bujold E; Morin V; Vallée M; Giguère Y; Gagné C; Rousseau F; Reinharz D J Obstet Gynaecol Can; 2013 Aug; 35(8):730-740. PubMed ID: 24007709 [TBL] [Abstract][Full Text] [Related]
3. Effectiveness and costs of non-invasive foetal RHD genotyping in rhesus-D negative mothers: a French multicentric two-arm study of 850 women. Darlington M; Carbonne B; Mailloux A; Brossard Y; Levy-Mozziconacci A; Cortey A; Maoulida H; Simon T; Rousseau A; Durand-Zaleski I; BMC Pregnancy Childbirth; 2018 Dec; 18(1):496. PubMed ID: 30547830 [TBL] [Abstract][Full Text] [Related]
4. High-throughput, non-invasive prenatal testing for fetal Rhesus D genotype to guide antenatal prophylaxis with anti-D immunoglobulin: a cost-effectiveness analysis. Saramago P; Yang H; Llewellyn A; Palmer S; Simmonds M; Griffin S BJOG; 2018 Oct; 125(11):1414-1422. PubMed ID: 29415334 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of first trimester non-invasive fetal RHD screening for targeted antenatal anti-D prophylaxis in RhD-negative pregnant women: a model-based analysis. Neovius M; Tiblad E; Westgren M; Kublickas M; Neovius K; Wikman A BJOG; 2016 Jul; 123(8):1337-46. PubMed ID: 26663771 [TBL] [Abstract][Full Text] [Related]
7. Costs and benefits of non-invasive fetal RhD determination. Teitelbaum L; Metcalfe A; Clarke G; Parboosingh JS; Wilson RD; Johnson JM Ultrasound Obstet Gynecol; 2015 Jan; 45(1):84-8. PubMed ID: 25380024 [TBL] [Abstract][Full Text] [Related]
8. [Economic analysis of the prevention of anti-D immunization]. Ravinet J; Carbonne B J Gynecol Obstet Biol Reprod (Paris); 2006 Feb; 35(1 Suppl):1S104-1S111. PubMed ID: 16495835 [TBL] [Abstract][Full Text] [Related]
9. A new fetal RHD genotyping test: costs and benefits of mass testing to target antenatal anti-D prophylaxis in England and Wales. Szczepura A; Osipenko L; Freeman K BMC Pregnancy Childbirth; 2011 Jan; 11():5. PubMed ID: 21244652 [TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of noninvasive fetal RhD blood group genotyping in nonalloimmunized and alloimmunized pregnancies. Gajic-Veljanoski O; Li C; Schaink AK; Guo J; Shehata N; Charames GS; de Vrijer B; Clarke G; Pechlivanoglou P; Okun N; Kandel R; Dooley J; Higgins C; Ng V; Sikich N Transfusion; 2022 May; 62(5):1089-1102. PubMed ID: 35170037 [TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of antenatal anti-D prophylaxis. Vick S; Cairns J; Urbaniak S; Whitfield C; Raafat A Health Econ; 1996; 5(4):319-28. PubMed ID: 8880168 [TBL] [Abstract][Full Text] [Related]
15. The economics of routine antenatal anti-D prophylaxis for pregnant women who are rhesus negative. Chilcott J; Tappenden P; Lloyd Jones M; Wight J; Forman K; Wray J; Beverley C BJOG; 2004 Sep; 111(9):903-7. PubMed ID: 15327602 [TBL] [Abstract][Full Text] [Related]
16. Cost-benefit analysis of indirect antiglobulin screening in Rh(D)-negative women at 28 weeks of gestation. Abbey R; Dunsmoor-Su R Obstet Gynecol; 2014 May; 123(5):938-945. PubMed ID: 24785843 [TBL] [Abstract][Full Text] [Related]
17. The continuing burden of Rh disease 50 years after the introduction of anti-Rh(D) immunoglobin prophylaxis: call to action. Visser GHA; Di Renzo GC; Spitalnik SL; Am J Obstet Gynecol; 2019 Sep; 221(3):227.e1-227.e4. PubMed ID: 31121145 [TBL] [Abstract][Full Text] [Related]
18. Routine antenatal anti-D prophylaxis for RhD-negative women: a systematic review and economic evaluation. Pilgrim H; Lloyd-Jones M; Rees A Health Technol Assess; 2009 Feb; 13(10):iii, ix-xi, 1-103. PubMed ID: 19210896 [TBL] [Abstract][Full Text] [Related]
19. Targeted antenatal anti-D prophylaxis for RhD-negative pregnant women: a systematic review. Runkel B; Bein G; Sieben W; Sow D; Polus S; Fleer D BMC Pregnancy Childbirth; 2020 Feb; 20(1):83. PubMed ID: 32033599 [TBL] [Abstract][Full Text] [Related]
20. Failures of intravenous Rh immune globulin prophylaxis: an analysis of the reasons for such failures. Bowman JM; Pollock JM Transfus Med Rev; 1987 Aug; 1(2):101-12. PubMed ID: 2856541 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]